Firstline pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2positive metastatic esophagogastric adenocarcinoma

Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 010d83e0f6ce870329d2f53a97926965b0d5ed40
First added on: Feb 11, 2025